Literature DB >> 16843843

An improved method of 18F peptide labeling: hydrazone formation with HYNIC-conjugated c(RGDyK).

Yun-Sang Lee1, Jae Min Jeong, Hyung Woo Kim, Young Soo Chang, Young Joo Kim, Mee Kyung Hong, Ganesha B Rai, Dae Yoon Chi, Won Jun Kang, Joo Hyun Kang, Dong Soo Lee, June-Key Chung, Myung Chul Lee, Young-Ger Suh.   

Abstract

Radiolabeled alpha(v)beta(3)-integrin antagonists are increasingly investigated as a means of imaging angiogenesis. Several methods of labeling alpha(v)beta(3)-integrin binding peptide with (18)F have been reported recently. In the present study, we devised a straightforward means for labeling Arg-Gly-Asp (RGD) peptide with (18)F via hydrazone formation between c(RGDyK)-hydrazinonicotinic acid (HYNIC) (3) and 4-[(18)F]-fluorobenzaldehyde ([(18)F]4). The resulting reaction mixture was purified by HPLC to give 4'-[(18)F]-fluorobenzylidenehydrazone-6-nicotinamide-c(RGDyK) ([(18)F]5). The conjugation efficiency of 3 and 4 to form [(18)F]5 was 95.2%, and the radiochemical purity of [(18)F]5 after purification was >99%. The specific activity of [(18)F]5 estimated by radio-HPLC was 20.5 GBq/mumol (end of synthesis). Competitive binding assay of c(RGDyK) (1) and 5 was performed using [(125)I]iodo-c(RGDyK) as a radioligand, and K(i) values were found to be 2.8 and 21.7 nM, respectively. For the biodistribution study, the angiogenic mouse model was established by inducing unilateral ischemia on the left hindlimbs of ICR mice after femoral artery ablation. Seven days after inducing ischemia, [(18)F]5 was administered to the mice through the tail vein. Ischemic muscle uptake of [(18)F]5 was significantly higher than that of normal muscle (P<.01). Specific uptake was confirmed by coinjection of 1 with [(18)F]5. Here, we successfully labeled RGD peptide with (18)F via hydrazone formation between 3 and 4, resulting to [(18)F]5. [(18)F]5 was found to have high affinity for alpha(v)beta(3)-integrin and to accumulate specifically in ischemic hindlimb muscle of mice. We suggest that (18)F labeling via formation of hydrazone between HYNIC peptide and [(18)F]4 is a useful method for labeling c(RGDyK), which can be applied for imaging angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16843843     DOI: 10.1016/j.nucmedbio.2006.04.004

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  7 in total

Review 1.  18 F-Labeling of Sensitive Biomolecules for Positron Emission Tomography.

Authors:  Hema S Krishnan; Longle Ma; Neil Vasdev; Steven H Liang
Journal:  Chemistry       Date:  2017-09-01       Impact factor: 5.236

Review 2.  Radiosyntheses using fluorine-18: the art and science of late stage fluorination.

Authors:  Erin L Cole; Megan N Stewart; Ryan Littich; Raphael Hoareau; Peter J H Scott
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

Review 3.  Positron emission tomography tracers for imaging angiogenesis.

Authors:  Roland Haubner; Ambros J Beer; Hui Wang; Xiaoyuan Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-08       Impact factor: 9.236

4.  Propargyl 4-[F]fluorobenzoate: A Putatively More Stable Prosthetic group for the Fluorine-18 Labeling of Biomolecules via Click Chemistry.

Authors:  Ganesan Vaidyanathan; Benjamin J White; Michael R Zalutsky
Journal:  Curr Radiopharm       Date:  2009-01-01

Review 5.  KSNM60: The History of Radiopharmaceutical Sciences in Korea.

Authors:  Ran Ji Yoo; Yun-Sang Lee; Kyo Chul Lee; Dong Wook Kim; Dong-Yeon Kim; Yearn Seong Choe; Jae Min Jeong
Journal:  Nucl Med Mol Imaging       Date:  2022-04-05

6.  Genome-free viral capsids as carriers for positron emission tomography radiolabels.

Authors:  Jacob M Hooker; James P O'Neil; Dante W Romanini; Scott E Taylor; Matthew B Francis
Journal:  Mol Imaging Biol       Date:  2008-04-25       Impact factor: 3.488

7.  Preclinical PET imaging of HIP/PAP using 1'-18F-fluoroethyl-β-D-lactose.

Authors:  Shaobo Yao; Yaping Luo; Zhenzhong Zhang; Guilan Hu; Zhaohui Zhu; Fang Li
Journal:  Oncotarget       Date:  2017-09-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.